EGFR and non-small cell lung carcinoma: The median overall survival (OS) appears longer in NSCLC patients with compound mutations than in those with single uncommon EGFR mutations, consistently across different retrospective studies (~31–33 vs. 12–17 months) [31,32,33,34,35].